Search

Search Results

• Durable complete response in a patient with BRAF-mutated advanced melanoma with ocular and skin toxicities from BRAF/MEK targeted therapy after checkpoint inhibitor treatment: a case report

  Carlotta Bertolina, Marinella Bertolotti, Claudia Leporati, Antonina Maria De Angelis, Sara Delfanti, Luigi Cerbone, Marco Ghiglione, Federica Grosso

  17-06-2025

  https://doi.org/10.4081/dr.2025.10324

  536

  PDF: 316

  HTML: 21

• Optimizing targeted therapy for metastatic melanoma: a combination of encorafenib and trametinib beyond standard protocols

  François Pélouard, Valérie Chedru-Legros, Catherine Nganoa, Anne Dompmartin, Jean-Matthieu L'Orphelin

  15-04-2025

  https://doi.org/10.4081/dr.2025.10036

  841

  PDF: 335

  SUPPLEMENTARY MATERIAL: 89

  HTML: 6
• 

  Severe and delayed-onset acneiform eruptions as an adverse reaction to regorafenib

  Haruhiko Otsuka, Takeshi Fukumoto, Naomi Kiyota, Chihiro Takemori, Haruki Jimbo, Chikako Nishigori

  01-01-2022

  https://doi.org/10.4081/dr.2022.9303

  1679

  PDF: 627

  HTML: 17

• Erythema nodosum-like panniculitis during BRAF inhibitor therapy for melanoma: never forget latent tuberculosis infection

  Alba Guglielmo, Lorenzo D'Alì, Maria Ludovica Deotto, Alessia Cimadamore, Gaetano Pascoletti, Elena Poletto, Alessandro Minisini

  04-06-2026

  https://doi.org/10.4081/dr.2026.10380

  428

  PDF: 244
• 

  Generalized keratosis pilaris induced by testosterone injections in a patient with CHARGE syndrome

  Fares Abdulmajed Alkhayal, Rima Bin Fadliah, Sarah Alasgah, Raed Almutiri, Yasser Alqubaisy

  21-04-2023

  https://doi.org/10.4081/dr.2023.9661

  1555

  PDF: 572

  HTML: 750